Polyvalent EBV Antigen Constructs for Robust T-Cell Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EBV vaccines have not been licensed for use in humans, and there is a need for effective vaccines to prevent EBV infection and treat EBV-associated malignancies and diseases such as multiple sclerosis.
Innovation Solution
Development of EBV antigen polypeptides, polynucleotides, and vectors that induce an immune response against EBV infection, including polyvalent antigen constructs comprising fragments of LMP1, LMP2, EBNA1, EBNA3A, and ZEBRA proteins, administered via adenovirus or vaccinia virus vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional single-antigen vaccines (e.g., gp350) are used, then the vaccine structure is simple and easy to manufacture, but the immune response is insufficient and fails to provide effective protection against EBV infection and associated diseases
Solution Approach 1:
The patent combines multiple EBV antigens (LMP1, LMP2, EBNA1, EBNA3A, and ZEBRA) into a single polyvalent vaccine construct. This merging of multiple antigenic components into one integrated vaccine formulation enables simultaneous stimulation of diverse immune responses against different EBV proteins, thereby enhancing overall vaccine effectiveness while maintaining a unified delivery system
Solution Approach 2:
The vaccine employs a composite antigen structure comprising fragments from five different EBV proteins (LMP1, LMP2, EBNA1, EBNA3A, and ZEBRA) assembled together. This composite approach creates a multi-component immunogen that targets multiple viral proteins concurrently, generating broader and more robust T-cell and antibody responses compared to single-antigen vaccines
2Reliability
If polyvalent antigen constructs with multiple fragments are used, then the immune response is robust and comprehensive, but the manufacturing process becomes more complex
Solution Approach 1:
Multiple antigen fragments from different EBV proteins are merged into a single recombinant polypeptide construct. This consolidation allows all antigen components to be produced simultaneously through a single expression system (bacterial, mammalian, or viral), simplifying manufacturing compared to producing and purifying each antigen separately
Solution Approach 2:
The polyvalent antigen construct serves multiple functions: it presents epitopes from LMP1, LMP2, EBNA1, EBNA3A, and ZEBRA proteins within a single molecular entity. This multi-functional design enables one vaccine formulation to elicit comprehensive immune responses against multiple EBV proteins, reducing the need for multiple separate vaccine components and simplifying production logistics
Data Source
AI summary
The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.